RecruitingNCT05447169

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Ming-Yuan Chen, MD, PhD
Sun Yat-sen University
Intervention
EBV antibodies test(diagnostic_test)
Enrollment
11625 target
Eligibility
30-62 years · MALE
Timeline
2022 – 2030

Study locations (1)

Collaborators

Wuzhou Red Cross Hospital · Zhongshan People's Hospital, Guangdong, China · Hunan Cancer Hospital · The Third Affiliated Hospital of Nanchang University · First People's Hospital of Foshan · Yuebei People's Hospital · Xiangya Hospital of Central South University · Changsha Central Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05447169 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma →

← Back to all trials